Travere Therapeutics

Travere’s Kidney Disease Drug Narrowly Misses Phase III Endpoint, Stock Tanks
Travere’s Kidney Disease Drug Narrowly Misses Phase III Endpoint, Stock Tanks
BioSpace
Travere Therapeutics
kidney disease
sparsentan
Filspari
clinical trials
Flag link:
Travere trips up but others are following in rare kidney disease
Travere trips up but others are following in rare kidney disease
EP Vantage
Travere Therapeutics
Filspari
focal segmental glomerulosclerosis
Flag link:
Travere’s FSGS therapy trial fails to meet primary efficacy endpoint
Travere’s FSGS therapy trial fails to meet primary efficacy endpoint
Clinical Trials Arena
Travere Therapeutics
sparsentan
focal segmental glomerulosclerosis
clinical trials
Flag link:
Travere’s Filspari reduces urine protein levels in adults with IgAN
Travere’s Filspari reduces urine protein levels in adults with IgAN
Clinical Trials Arena
Travere Therapeutics
Filspari
IgA nephropathy
clinical trials
Flag link:
Biotech heads towards big catalysts
Biotech heads towards big catalysts
EP Vantage
biotech
clinical trials
Alnylam Pharmaceuticals
Arcus Biosciences
Argenx
Arrowhead Pharmaceuticals
Axsome Therapeutics
Bavarian Nordic
FibroGen
Gilead Sciences
Incyte
Morphic Therapeutic
PTC Therapeutics
Syndax Pharmaceuticals
Travere Therapeutics
Vaxcyte
Flag link:
Biotech’s key upcoming clinical results
Biotech’s key upcoming clinical results
EP Vantage
clinical trials
Acadia Pharmaceuticals
Argenx
Arrowhead Pharmaceuticals
Biomarin
BioNTech
Daiichi Sankyo
Day One
EQRx
Fate Therapeutics
FibroGen
Gilead Sciences
Idorsia
Immunogen
Intellia Therapeutics
Karuna Therapeutics
Moderna Therapeutics
Regeneron
Roche
Travere Therapeutics
Vaxcyte
Flag link:
FDA’s liver safety request set to delay decision on Travere’s kidney drug
FDA’s liver safety request set to delay decision on Travere’s kidney drug
Fierce Biotech
Travere Therapeutics
kidney disease
REMS
FDA
Flag link:
Brace for an end-of-year boost to drug approvals
Brace for an end-of-year boost to drug approvals
EP Vantage
FDA
drug approvals
Alnylam Pharmaceuticals
Apellis Pharmaceuticals
Bristol Myers Squibb
Eli Lilly
Gilead Sciences
Mirati Therapeutics
Moderna Therapeutics
Provention Bio
Roche
TG Therapeutics
Travere Therapeutics
Flag link:
Travere fails to convince regulators to consider accelerated approval for a rare kidney disease — again
Travere fails to convince regulators to consider accelerated approval for a rare kidney disease — again
Endpoints
Travere Therapeutics
Martin Shkreli
sparsentan
FDA
kidney disease
Flag link:
Vifor Licenses Rare Kidney Disease Drug in Comeback for Travere
Vifor Licenses Rare Kidney Disease Drug in Comeback for Travere
BioSpace
Vifor Pharma
Travere Therapeutics
kidney disease
Flag link:
Several months after rebranding, an old Martin Skhreli company touts promising pivotal data in a rare kidney disorder
Several months after rebranding, an old Martin Skhreli company touts promising pivotal data in a rare kidney disorder
Endpoints
Calliditas
Martin Shkreli
Nefecon
Travere Therapeutics
Flag link:
FDA sets back Travere's plans for kidney disease drug approval
FDA sets back Travere's plans for kidney disease drug approval
Fierce Biotech
Travere Therapeutics
kidney disease
clinical trials
FDA
Retrophin
Martin Shkreli
Flag link:
Retrophin no more: Shkreli's legacy disappears as former company becomes Travere Therapeutics
Retrophin no more: Shkreli's legacy disappears as former company becomes Travere Therapeutics
Endpoints
Retrophin
Martin Shkreli
Travere Therapeutics
Flag link: